As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scaliaasked CEO David Ricks if the company ...
Sales of Lilly’s top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter of 2024 while its obesity treatment counterpart Zepbound brought in $1.9 billion ...
In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...
The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential setback in the company’s efforts to join the booming weight ...
The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...
Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...
The study lasts up to five weeks and involves four to five visits to the Center for Human Nutrition. The study involves measuring body composition, sleep, mood, diet and other aspects of health.
A man lost a whopping 169 pounds — more than the weight of a washing machine — in a year, and he managed it all with ...
When Jeanne began to seriously consider taking Zepbound, one of the new-generation weight-loss drugs, she had the briefest of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback